Log in

NASDAQ:VCYTVeracyte Stock Price, Forecast & News

$29.09
+0.63 (+2.21 %)
(As of 07/15/2020 04:00 PM ET)
Add
Compare
Today's Range
$27.50
Now: $29.09
$29.11
50-Day Range
$23.06
MA: $26.16
$29.54
52-Week Range
$13.90
Now: $29.09
$31.18
Volume410,400 shs
Average Volume529,884 shs
Market Capitalization$1.46 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.84
Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas solutions for a complex landscape in thyroid nodule diagnosis to physicians; Percepta Bronchial Genomic Classifier solution for use in lung cancer diagnosis; and Envisia Genomic Classifier solution for the diagnosis of idiopathic pulmonary fibrosis. It sells its products through product specialists, account managers, and medical science specialists. Veracyte, Inc. has a strategic collaboration with Johnson & Johnson, LLC and Johnson & Johnson's Lung Cancer Initiative to advance diagnostics of a nasal swab test for early lung cancer detection; a research collaboration with Loxo Oncology for the development of therapies for patients with genetically defined cancers; and an agreement with Johnson & Johnson Services, Inc. for the development and commercialization of novel diagnostic tests to detect lung cancer. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Read More
Veracyte logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.23 out of 5 stars


Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VCYT
CUSIPN/A
Phone650-243-6300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$120.37 million
Book Value$4.90 per share

Profitability

Net Income$-12,600,000.00

Miscellaneous

Employees270
Market Cap$1.46 billion
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive VCYT News and Ratings via Email

Sign-up to receive the latest news and ratings for VCYT and its competitors with MarketBeat's FREE daily newsletter.

Veracyte (NASDAQ:VCYT) Frequently Asked Questions

How has Veracyte's stock been impacted by COVID-19 (Coronavirus)?

Veracyte's stock was trading at $23.55 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, VCYT shares have increased by 23.5% and is now trading at $29.09. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Veracyte?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Veracyte.

When is Veracyte's next earnings date?

Veracyte is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Veracyte.

How were Veracyte's earnings last quarter?

Veracyte Inc (NASDAQ:VCYT) released its quarterly earnings data on Wednesday, May, 6th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by $0.06. The biotechnology company had revenue of $31.12 million for the quarter, compared to the consensus estimate of $30.31 million. Veracyte had a negative return on equity of 9.68% and a negative net margin of 18.36%. View Veracyte's earnings history.

What price target have analysts set for VCYT?

3 brokerages have issued twelve-month price targets for Veracyte's stock. Their forecasts range from $30.00 to $35.00. On average, they expect Veracyte's share price to reach $32.33 in the next year. This suggests a possible upside of 11.1% from the stock's current price. View analysts' price targets for Veracyte.

Has Veracyte been receiving favorable news coverage?

Media coverage about VCYT stock has been trending negative on Thursday, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Veracyte earned a media sentiment score of -2.9 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about Veracyte.

Are investors shorting Veracyte?

Veracyte saw a increase in short interest during the month of June. As of June 15th, there was short interest totaling 5,410,000 shares, an increase of 5.0% from the May 31st total of 5,150,000 shares. Based on an average daily trading volume, of 516,900 shares, the short-interest ratio is presently 10.5 days. Approximately 11.3% of the shares of the company are sold short. View Veracyte's Current Options Chain.

Who are some of Veracyte's key competitors?

What other stocks do shareholders of Veracyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), CA (CA), Crispr Therapeutics (CRSP), AbbVie (ABBV), Advanced Micro Devices (AMD), Endologix (ELGX), BlackRock (BLK), InVitae (NVTA), Gilead Sciences (GILD) and Alibaba Group (BABA).

Who are Veracyte's key executives?

Veracyte's management team includes the following people:
  • Ms. Bonnie H. Anderson, Co-Founder, Chairman & CEO (Age 61)
  • Mr. Christopher M. Hall, Pres & COO (Age 50)
  • Mr. Keith S. Kennedy CFA, CPA, CFO & Sec. (Age 49)
  • Dr. Giulia C. Kennedy Ph.D., Chief Scientific & Medical Officer (Age 60)
  • Mr. Ashish Kheterpal, Chief Information Officer

What is Veracyte's stock symbol?

Veracyte trades on the NASDAQ under the ticker symbol "VCYT."

Who are Veracyte's major shareholders?

Veracyte's stock is owned by a variety of retail and institutional investors. Top institutional investors include Envestnet Asset Management Inc. (0.05%) and Exchange Traded Concepts LLC (0.03%). Company insiders that own Veracyte stock include Bonnie H Anderson, Christopher M Hall, Evan/ Fa Jones, Giulia C Kennedy, Jesse I Treu, John Walter Hanna Jr, Keith Kennedy and Robert S Epstein. View institutional ownership trends for Veracyte.

Which major investors are selling Veracyte stock?

VCYT stock was sold by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. Company insiders that have sold Veracyte company stock in the last year include Bonnie H Anderson, Evan/ Fa Jones, Giulia C Kennedy, John Walter Hanna Jr, Keith Kennedy, and Robert S Epstein. View insider buying and selling activity for Veracyte.

Which major investors are buying Veracyte stock?

VCYT stock was bought by a variety of institutional investors in the last quarter, including Exchange Traded Concepts LLC. View insider buying and selling activity for Veracyte.

How do I buy shares of Veracyte?

Shares of VCYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Veracyte's stock price today?

One share of VCYT stock can currently be purchased for approximately $29.09.

How big of a company is Veracyte?

Veracyte has a market capitalization of $1.46 billion and generates $120.37 million in revenue each year. The biotechnology company earns $-12,600,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. Veracyte employs 270 workers across the globe.

What is Veracyte's official website?

The official website for Veracyte is www.veracyte.com.

How can I contact Veracyte?

Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-243-6300 or via email at [email protected]

This page was last updated on 7/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.